Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer

• Published in: Breast (Edinburgh) Vol. 57; pp. 43 - 48
• Main Authors: Lapidari, Pietro, Gbenou, Arnauld, Havas, Julie, Martin, Elise, Pistilli, Barbara, Martin, Anne-Laure, Everhard, Sibille, Coutant, Charles, Cottu, Paul, Lesur, Anne, Lerebours, Florence, Tredan, Olivier, Vanlemmens, Laurence, Jouannaud, Christelle, Levy, Christelle, Rigal, Olivier, Fournier, Marion, Andre, Fabrice, Vaz-Luis, Ines, Di Meglio, Antonio
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.06.2021; Elsevier
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - psychology; Cancer; Female; Granulocyte Colony-Stimulating Factor - therapeutic use; Granulocyte-colony stimulating factors; Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects; Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use; Granulocytes; Health-related quality-of-life; Humans; Life Sciences; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Patient-reported outcomes; Quality of Life; Short Communication; Survivorship; Granulocyte-colony stimulating factors; Health-related quality-of-life; Breast cancer; Patient-reported outcomes; Survivorship
• ISSN: 0960-9776; 1532-3080; 1532-3080
• DOI: 10.1016/j.breast.2021.02.014

We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498). Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time. •Studies on long-term side effects of G-CSF, including on quality of life, are lacking.•We evaluated PROs and hematological values until year-4 after diagnosis among women with early breast cancer receiving G-CSF.•49% women treated with adjuvant chemotherapy in CANTO (N = 2920) used G-CSF.•Long-term PROs and hematological values were not substantially different in women using G-CSF or not.•There were slightly worse outcomes at year-4 in patients using G-CSF, although of trivial clinical significance.